Year: 2024
Type: article
Abstract: of competition should be permitted on welfare grounds.Revision of regulations around the use of omeprazole during competition by governing bodies is necessary to safeguard the ethical use of horses in sport. MULTINODUL AR PULMONARY FIB ROS ISThis study by Amanda Craven and co-workers in the United States and the Netherlands described the clinical findings and outcome predictors for multinodular pulmonary fibrosis (EMPF) in 46 horses.Radiographic (n = 27) and ultrasonographic studies (n = 19) from EMPF horses and bronchoalveolar lavage fluid (BALF) cytology from 6 EMPF and 13 asthma cases were independently reviewed and blinded to diagnosis and outcome.Associations between predictor variables and survival were assessed by predictor screening followed by Fisher's exact and Wilcoxon rank sum tests.Primary clinical findings were weight loss (36/46, 78%), increased respiratory effort (33/46, 72%), tachypnoea (32/46, 70%) and fever (18/46, 39%).Macrophage atypia was seen in more EMPF than asthmatic horse BALF (67% vs. 8%).Equine herpesvirus 5 (EHV-5) was detected in 24 of 30 (80%) and hyperfibrinogenaemia in 25 of 28 (89%) cases.Twenty-seven of 46 horses (59%) and 11 of 45 (24%) survived to discharge and to 3 months, respectively.Three-month survival was associated with lower median (range) respiratory rates (30 [24-36] vs. 41 [30-60] breaths/min), and higher BALF lymphocyte: neutrophil ratios (4.7 [1.4-22] vs. 0.47 [0.11-1.9])and blood lymphocyte counts (1.25 [0.93-2.55] vs. 0.90 [0.70-1.24]× 10 9 /L).Imaging findings, EHV-5 detection, and corticosteroid treatment were not associated with survival.Fever is not a sensitive clinical sign of EMPF.Diagnostic testing should be pursued for horses with increased respiratory rate and effort and weight loss.The prognosis for EMPF horses is poor.Corticosteroid treatment does not improve 3-month survival. EQUINE NEUROA XONAL DYS TROPHYThis study by Alexis Powers and co-workers in the United States aimed to evaluate the clinical phenotype, blood vitamin E concentrations before and after supplementation and pedigree in a cohort of Gypsy Vanner (GV) horses with a high prevalence of neurologic disease suspicious for equine neuroaxonal dystrophy/degenerative myeloencephalopathy (eNAD/EDM) and also to confirm eNAD/EDM in GVs through post-mortem evaluation.Neurologic examination was performed on all 26 GVs in this study, which were from one farm in California and two cases from the Midwestern US.Pre-supplementation blood vitamin E concentration was assessed in 17 GVs.Twenty-three were supplemented orally with 10 IU/kg of liquid RRR-alpha-tocopherol once daily for 28 days.Vitamin E concentration was measured in 23 GVs after supplementation, of which 15 (65%) had pre-supplementation measurements.Two clinically affected GVs from California and the two Midwestern cases had necropsy confirmation of eNAD/EDM.Pre-supplementation blood vitamin E concentration was ≤2.0 μg/ mL in 16/17 (94%) of GVs from California.Post-supplementation concentration varied, with a median of 3.39 μg/mL (range, 1.23-13.87μg/mL), but only 12/23 (52%) were normal (≥3.0 μg/mL).Normalisation of vitamin E was significantly associated with increasing age.Euthanised horses (n = 4) had eNAD/EDM confirmed at necropsy.The authors concluded that GVs could have a genetic predisposition to eNAD/EDM.Vitamin E supplementation should be considered and monitored in young GVs.
Source: Equine Veterinary Education
DOI: 10.1111/eve.14053
Author: Sue Wright
Language: English
Subfield: Equine
Field: Veterinary
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4404070127